J

Johnson & Johnson

Global healthcare company offering pharma, devices.

Senior Manager – Finance IT Deployment & Integration Lead

Full-TimeDeadline 10/20/26
€82.9k - €144.2k/yr
Expert
Maidenhead, UK
HybridThree days per week in a J&J office required.

About the job

Requirements
  • At least 14 years of relevant functional experience with SAP ECC6 FI/CO, S/4HANA Finance, Central Finance, and enterprise deployment programs, including at least 3 years of S/4HANA implementation experience.
  • Experience with large-scale ERP deployments, transformation programs, and finance technology teams.
  • Expertise in S/4HANA Finance, SAP Central Finance, deployment and cutover management, systems integration, data migration, SAP cloud infrastructure, SAP BTP, finance process transformation, data strategy, governance, technology and process definition, financial accounting, reporting, close optimization, and continuous accounting.
  • Knowledge of financial accounting.
  • Strong leadership, communication, stakeholder management, interpersonal, collaboration, and team-building skills.
Responsibilities
  • Lead deployment, integration, and adoption of strategic Finance transformation solutions across the region.
  • Drive end-to-end deployment activities for SAP Finance, S/4HANA, and related Finance platforms while aligning global standards with regional business needs.
  • Lead deployment planning and execution, ensuring readiness across business processes, technology, data, controls, training, and support models.
  • Coordinate and govern end-to-end integration across Finance, Supply Chain, Commercial, HR, and external systems.
  • Develop and manage deployment, cutover, hypercare, and stabilization plans for go-live readiness.
  • Partner with business leaders, process owners, deployment teams, and technology organizations to align strategies, resolve risks, and drive adoption.
  • Establish deployment governance frameworks and monitor risks, dependencies, issues, and compliance requirements.
  • Partner with global program teams, system integrators, and regional stakeholders to deliver deployment activities on schedule and within scope.
  • Co-lead a global team of finance technology and deployment professionals across multiple domains and locations.
Desired Qualifications
  • Twenty or more years of relevant experience leading large-scale ERP deployments, transformation programs, and/or finance technology teams.
  • Technical expertise in S/4HANA, SAP Central Finance, deployment and cutover management, SAP BTP, systems integration, data migration, governance, technology, and process definition.
  • Experience with Invoice to Cash, Procure to Pay, Asset Management, Project Accounting, Treasury, or Finance Master Data Management.
  • Analytical reasoning, consulting, cost management, developing others, human-computer interaction, inclusive leadership, leadership, people performance management, performance measurement, product development, product strategy, project management methodology, research and development, resource management, software development management, strategic supply chain management, and team management.

About the company

Johnson & Johnson operates in three main areas—pharmaceuticals, medical devices, and consumer health products—serving consumers, healthcare professionals, and institutions worldwide. It develops prescription medicines, sells surgical and vision care devices, and offers over-the-counter and personal care products, funded by direct sales, partnerships, and distribution agreements, with heavy investment in research and development. The company differentiates itself by combining three complementary businesses under one umbrella and maintaining a global footprint with an emphasis on science, innovation, and inclusive culture. Its goal is to help people live healthier lives by delivering reliable, high-quality healthcare products and solutions that improve patient outcomes.

Company Size

10,001+

Company Stage

IPO

Headquarters

New Brunswick, New Jersey

Founded

1886

Get referred to Johnson & Johnson

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Second-quarter 2026 sales rose 6.6% to $25.3 billion, with raised full-year guidance.
  • TREMFYA posted $2 billion quarterly sales in July 2026, growing 72.5%.
  • CAPLYTA met its bipolar mania primary endpoint on September 21, 2026.

What critics are saying

  • Talc litigation still threatens cash flow after the $5.5 billion settlement announced July 2026.
  • Apollo's orthopedics talks signal DePuy Synthes weakness and forced portfolio shrinkage.
  • AbbVie's etentamig and biosimilars pressure CARVYKTI, TREMFYA, and post-STELARA growth.

What makes Johnson & Johnson unique

  • J&J has 28 billion-dollar products, reducing dependence on any single franchise.
  • TREMFYA and DARZALEX offset STELARA erosion, proving resilient portfolio management.
  • CAPLYTA, CARVYKTI, and RYBREVANT deepen leadership across psychiatry, cell therapy, and oncology.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Remote Work Options

Performance Bonus

Growth & Insights and Company News

Headcount

6 month growth

↓ -2%

1 year growth

↓ -2%

2 year growth

↓ -1%
Yahoo Finance
Sep 18th, 2026
J&J stock trades at 28x earnings, but STELARA biosimilar hit distorts valuation

Johnson & Johnson stock has surged 57% over the past year, outpacing the S&P 500's 17% return. Trading at approximately $270 per share, the stock appears expensive at 28.3 times trailing earnings. However, those trailing figures include STELARA, which lost market share to biosimilar competition and reduced operational sales growth by 460 basis points in Q2 2026. Excluding STELARA, the company achieved double-digit growth. The forward outlook looks more attractive, with the stock trading at 24.1 times fiscal 2026 earnings and 20.9 times 2027 estimates. Johnson & Johnson's portfolio includes 28 products generating over $1 billion annually each, with trailing twelve-month revenue near $98 billion. Meanwhile, TREMFYA grew 71% in Q2 2026, becoming the fastest-growing advanced therapy in Crohn's disease and ulcerative colitis. Operating margins improved to 26.8% from a three-year average of 25.7%, supporting expectations for continued margin expansion.

Yahoo Finance
Sep 14th, 2026
Apollo in talks to acquire J&J's orthopedics unit for $20B

Johnson & Johnson shares rose 1.3% in pre-market trading following reports that Apollo Global Management is in discussions to acquire its orthopedics business for approximately $20 billion. Bloomberg News reported the potential deal could be finalised within weeks, citing people familiar with the matter. The orthopedics division generated $9.3 billion in revenue in 2025. However, the business has faced thousands of lawsuits related to its hip replacement devices. No transaction has been confirmed. Investors responded positively to news of the reported discussions and the potential valuation of the orthopedics unit.

Yahoo Finance
Sep 3rd, 2026
J&J rises 1% as AbbVie's myeloma drug shows 74% response rate

Johnson & Johnson shares rose roughly 1% to $277.96 Thursday after AbbVie announced its experimental multiple-myeloma drug, etentamig, achieved a 74% response rate and reduced the risk of disease progression or death by 60% compared to standard therapies. AbbVie's trial positions a convenient monthly treatment in the myeloma market for potential outpatient use. However, J&J is defending its growing franchise, with Carvykti driving 6.8% operational growth in Innovative Medicine during the second quarter. According to Reuters, etentamig appears most differentiated after CAR-T therapy rather than as a direct Carvykti substitute. The market is treating AbbVie's advancement as category expansion rather than a direct threat to J&J. J&J's current share price stands 44.08% above its $192.92 valuation estimate, making future safety and durability data critical for investors.

Yahoo Finance
Sep 1st, 2026
P&G commits $10B in dividends amid 2.8B productivity savings while J&J's 28.5% stock surge masks mid-2027 spinoff risk

Procter & Gamble's dividend strategy is outpacing Johnson & Johnson's despite J&J's stronger stock performance this year. J&J's forward annualised dividend of $5.36 exceeds P&G's $4.354, but its planned mid-2027 DePuy Synthes spinoff threatens its dividend streak. P&G CEO Shailesh Jejurikar committed $10 billion in dividends and $5 billion in buybacks for fiscal 2027, supported by $2.8 billion in productivity savings. The company returned over $15 billion to shareholders in fiscal 2026, including more than $10 billion in dividends. J&J's stock surged 28.5% year-to-date versus P&G's 1.3% gain, driven by strong product performance. However, the upcoming spinoff poses uncertainty, as similar corporate events have disrupted other companies' dividend streaks. P&G faces no such structural risk.

Yahoo Finance
Aug 29th, 2026
J&J stock surges 52.8% in a year, outpacing consumer staples sector with strong pharma growth

Johnson & Johnson has significantly outperformed the consumer staples sector, with shares rising 52.8% over the past 52 weeks compared to the State Street Consumer Staples Select Sector SPDR Fund's 6.5% gain. The New Brunswick-based healthcare giant, valued at $640.5 billion, has seen particularly strong momentum recently, climbing 16.1% over three months. The company's strong performance follows solid second-quarter results released on 15 July, where sales increased 6.6% year-over-year to $25.31 billion. Adjusted earnings per share of $2.90 exceeded market expectations. Johnson & Johnson raised its full-year guidance, projecting adjusted EPS of $11.58 and sales of $101.1 billion. The stock currently trades just 3.1% below its 52-week high of $276.47, reached on 19 August.